Wellington Management Group
RNAC icon

Wellington Management Group’s Cartesian Therapeutics RNAC Stock Holding History

Wellington Management Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,066
Closed -$187K – 2177
2022
Q1 		$187K Sell
5,066
-56
-1% -$3.5K ﹤0.01% 2075
2021
Q4 		$501K Buy
+5,122
New +$551K ﹤0.01% 1984

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group's RNAC Position: Q2 2022 in Review

Wellington Management Group sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 5,066 shares — an estimated $187K sold.

Wellington Management Group first reported a position in RNAC in Q4 2021 and held it in 2 quarters. The position peaked at $501K in Q4 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

  • Wellington Management Group reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wellington Management Group sold 5,066 Cartesian Therapeutics shares in Q2 2022, an estimated $187K.
  • Wellington Management Group first reported a position in Cartesian Therapeutics in Q4 2021 and held it in 2 quarters.
  • Wellington Management Group's Cartesian Therapeutics position peaked at $501K in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Wellington Management Group's 13F filing for Q2 2022, filed 15 Aug 2022.